Retatrutide Dosage Guide: What We Know So Far

Retatrutide dosage is one of the hottest topics in the peptide world right now, and honestly, we're still learning. Retatrutide is newer than semaglutide and tirzepatide, and human data is still emerging. I'm going to break down what we know from clinical trials, what people are doing off-label, and what the dosing recommendations actually mean.

What Is Retatrutide and How It Works

Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist. Translation: it activates three different metabolic pathways related to weight loss and blood sugar control. This triple mechanism is why early data suggests it might be more effective than semaglutide or tirzepatide.

The clinical trials were originally run for diabetes, but the weight loss results were so pronounced that interest exploded for weight loss applications.

Clinical Trial Dosing Protocols

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) used weekly subcutaneous injections with dose escalation over 48 weeks. The trial tested four target maintenance doses: 1 mg, 4 mg, 8 mg, and 12 mg weekly. The 8 mg and 12 mg arms used a stepwise escalation. The 12 mg titration arm went 2 mg → 4 mg → 8 mg → 12 mg, with each step held for several weeks.

• 1 mg weekly (low-dose arm, no escalation)
• 4 mg weekly (titrated from 2 mg starting dose)
• 8 mg weekly (titrated 2 → 4 → 8 mg)
• 12 mg weekly (titrated 2 → 4 → 8 → 12 mg)

These doses are for weekly subcutaneous injection. Retatrutide has a long half-life that supports once-weekly dosing.

Weight Loss Results by Dose

At 48 weeks in the Phase 2 obesity trial, mean weight loss was approximately 17% on the 4 mg arm, 23% on the 8 mg arm, and 24% on the 12 mg arm. The 1 mg arm produced approximately 8% loss. These are placebo-corrected averages over the full 48-week trial — not 12 to 16 weeks. Earlier reports from the press cycle that conflated short-window loss with the 48-week endpoint should be treated skeptically; the high-percentage figures took the better part of a year of weekly dosing to reach.

For context, semaglutide (Wegovy) at 2.4 mg weekly produced approximately 15% mean loss in STEP 1 over 68 weeks, and tirzepatide (Zepbound) at 15 mg produced approximately 21% mean loss in SURMOUNT-1 over 72 weeks. Retatrutide at the high-dose arm appears modestly more effective than tirzepatide, but the trials use different timeframes and populations, so direct comparison is approximate.

Phase 3 (the TRIUMPH program) is ongoing. FDA approval is most likely 2027 or 2028 based on typical timelines from Phase 3 readout to approval.

Current Off-Label Dosing Approaches

Retatrutide is not FDA approved as of April 2026. Off-label dosing is emerging through telehealth-affiliated compounding pharmacies and from research peptide sources. Community protocols vary, and they do not necessarily mirror the published trial titration. Some users start at 1-2 mg weekly and escalate; others follow the trial's stepwise approach. There is no validated short-cycle protocol — the published efficacy figures come from the 48-week trial window, and shorter cycles will produce proportionally smaller results.

If you are following the Phase 2 trial as a reference, the conservative path is to start at 2 mg weekly, hold each step for at least four weeks, and escalate only if tolerated. Pushing past 12 mg has no published trial support.

Side Effects at Different Doses

The most common side effects in the trial were gastrointestinal — nausea, diarrhea, and vomiting — and they were dose-dependent. The 12 mg arm had higher GI adverse-event rates than the 1 mg arm, which is consistent with the broader GLP-1 literature. Nausea typically peaks shortly after a dose escalation step and improves over the following one to two weeks as tolerance develops.

At 1-2 mg weekly: GI side effects are usually mild. Many participants report little or nothing.

At 4-8 mg weekly: Nausea is common, especially in the days following a step up. Most people adapt within a week.

At 12 mg weekly: Nausea, diarrhea, and reduced appetite are more pronounced. A subset of trial participants discontinued at this dose for tolerability.

As with semaglutide and tirzepatide, the boxed warning on the GLP-1 class flags personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) as contraindications. Pancreatitis and gallbladder events are also class-level concerns.

Appetite Suppression

The central mechanism of weight loss is reduced caloric intake driven by appetite suppression and slower gastric emptying. Hunger and food cravings drop; meals feel satisfying at smaller volumes.

At trial doses above 4 mg, appetite suppression can be substantial enough that protein intake becomes a deliberate decision rather than a hunger-driven one. The standard recommendation in obesity-medicine practice is 1.6 grams of protein per kilogram of body weight per day during a GLP-1 cycle, both to preserve lean mass and to maintain a sense of meal satisfaction.

Comparing to Semaglutide and Tirzepatide

Semaglutide is a GLP-1 receptor agonist. Effective weight-loss dose is 2.4 mg weekly (Wegovy), reached by titrating through 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over roughly 16 weeks.

Tirzepatide is a dual GLP-1 / GIP receptor agonist. Effective weight-loss doses are 5, 10, or 15 mg weekly (Zepbound), reached by titrating in 2.5 mg steps every four weeks.

Retatrutide adds glucagon receptor activation as a third pathway. Phase 2 data shows it produces somewhat greater mean weight loss than tirzepatide at the upper-dose arm, but it is not yet approved and the long-term safety profile beyond 48 weeks is still being characterized in Phase 3.

Pricing and Availability

Retatrutide isn't available through mainstream pharmacies yet. Telehealth clinics are starting to offer it, often through compounding arrangements. Pricing varies wildly.

I've seen pricing from $300-800 per month depending on the dose and the clinic. This is higher than semaglutide (usually $200-400) but comparable to tirzepatide pricing.

From Limitless Life Peptides' resources, the consensus is that as retatrutide becomes more available, pricing should normalize lower.

Important Considerations Before Using

You need to be realistic about side effects. Retatrutide will likely suppress your appetite significantly. If you don't like that feeling or if you struggle to eat enough with suppressed appetite, this might not be right for you.

You need adequate protein intake. The appetite suppression can lead to muscle loss if you're not intentional about protein. Some people do high-protein drinks even when not hungry to protect muscle.

You need to be consistent. Weekly injections need to happen on schedule. Missing doses reduces effectiveness.

Realistic Expectations

The Phase 2 trial averaged its weight-loss endpoints at 24 weeks and 48 weeks. Translating to a personal trajectory: visible appetite suppression starts within the first one to two weeks, but the bulk of weight loss accumulates over months, not weeks. Trial participants on the 8 mg or 12 mg arms typically reached approximately 10% loss by 24 weeks and continued to roughly 23-24% by 48 weeks.

Plateau is real. After the appetite-suppression window stabilizes, further loss generally requires deliberate caloric awareness rather than relying on hunger reduction alone.

The Future of Retatrutide

Phase 3 trials (the TRIUMPH program) are ongoing. Based on standard Phase 3 timelines, FDA approval is most plausible in 2027 or 2028 rather than 2026. Once approved, retatrutide will move to mainstream pharmaceutical channels, which historically increases supply and pulls cash prices down over the first year.

Key Takeaways

• Phase 2 obesity-trial doses were 1, 4, 8, and 12 mg weekly, titrated stepwise — not 0.25 → 2.5 mg
• Mean weight loss at 48 weeks was approximately 8% (1 mg), 17% (4 mg), 23% (8 mg), and 24% (12 mg)
• Side effects (nausea, diarrhea, vomiting) are dose-dependent and broadly similar to other GLP-1 class drugs
• Retatrutide is not FDA approved as of April 2026; FDA approval is most likely 2027-2028
• Boxed-warning contraindications (personal or family history of MTC or MEN 2) apply across the GLP-1 class
• Adequate protein intake (≈1.6 g/kg/day) is the standard recommendation to preserve lean mass during a GLP-1 cycle
• The dramatic weight-loss figures in headlines come from 48-week trial endpoints, not short-window outcomes